Following the publication of the Review by Michelle Kreke, Rachel Ruckdeschel Smith, Linda Marbán and Eduardo Marbán, ‘Cardiospheres and cardiosphere-derived cells as therapeutic agents following myocardial infarction’, published in the September 2012 issue of Expert Review of Cardiovascular Therapy (Expert Rev. Cardiovasc. Ther. 10[9], 1185–1194 [2012]), it has been brought to our attention that the websites on page 1194 were incorrectly printed as:
Websites
- ClinicalTrials.gov. Autologous human cardiac-derived stem cell to treat ischemic cardiomyopathy (ALCADIA). http://clinicaltrials.gov/ct2/show/NCT00981006?term=cells+and+fgf&rank=3
- ClinicalTrials.gov. The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study). http://clinicaltrials.gov/ct2/show/NCT01087996
- ClinicalTrials.gov. Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration (ALLSTAR). http://clinicaltrials.gov/ct2/show/NCT014 58405?term=allstar&rank=1
- ClinicalTrials.gov. Autologous bone marrow derived stem cells for acute myocardial infarction. http://clinicaltrials.gov/ct2/show/NCT01167751?term=nct01167751&rank=1
- ClinicalTrials.gov. Endocardial stem cells approach efficacy (ESCAPE). http://clinicaltrials.gov/ct2/show/NCT00841958
- ClinicalTrials.gov. The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells (BM-MNC) on all-cause mortality in acute myocardial infarction (BAMI). http://cordis.europa.eu/projects/ rcn/101806_en.htmlhttp://clinicaltrials.gov/ct2/show?term=cardiac+and+stem+cel ls&rcv_s=05%2F01%2F2011&rcv_ e=04%2F07%2F2012&rank=22
- ClinicalTrials.gov. Safety and efficacy of ADRCs delivered via the intracoronary route in the treatment of patients with ST-elevation acute myocardial infarction (ADVANCE). http://clinicaltrials.gov/ct2/show/NCT012 16995?term=advance&rank=1
- Efficacy and safety of targeted intramyocardial delivery of auto CD34+ stem cells for improving exercise capacity in subjects with refractory angina. http://clinicaltrials.gov/ct2/show/NCT015 08910?term=renew+cd34&rank=1
- ClinicalTrials.gov. Bone marrow-derived AC133+ and mono-nuclear cells (MNC) implantation in myocardial infarction (MI) patient. http://clinicaltrials.gov/ct2/show/NCT01187654
Websites
- ClinicalTrials.gov. Autologous human cardiac-derived stem cell to treat ischemic cardiomyopathy (ALCADIA). http://clinicaltrials.gov/ct2/show/NCT00981006?term=cells+and+fgf&rank=3
- ClinicalTrials.gov. Endocardial stem cells approach efficacy (ESCAPE). http://clinicaltrials.gov/ct2/show/NCT00841958
- ClinicalTrials.gov. The percutaneous stem cell injection delivery effects on neomyogenesis pilot study (The POSEIDON-Pilot Study). http://clinicaltrials.gov/ct2/show/NCT01087996
- ClinicalTrials.gov. Autologous bone marrow derived stem cells for acute myocardial infarction. http://clinicaltrials.gov/ct2/show/NCT01167751
- ClinicalTrials.gov. Bone marrow derived AC 133+ and mono-nuclear cells (MNC) implantation in myocardial infarction (MI) patient. http://clinicaltrials.gov/ct2/show/NCT01187654
- ClinicalTrials.gov. Allogeneic heart stem cells to achieve myocardial regeneration (ALLSTAR). http://clinicaltrials.gov/ct2/show/NCT01458405
- ClinicalTrials.gov. Efficacy and safety of targeted intramyocardial delivery of auto CD34+ stem cells for improving exercise capacity in subjects with refractory angina (RENEW). http://clinicaltrials.gov/ct2/show/NCT01508910
- ClinicalTrials.gov. The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells (BM-MNC) on all-cause mortality in acute myocardial infarction (BAMI). http://clinicaltrials.gov/ct2/show/NCT01569178
- ClinicalTrials.gov. Safety and efficacy of ADRCs delivered via the intracoronary route in the treatment of patients with ST-elevation acute myocardial infarction (ADVANCE). http://clinicaltrials.gov/ct2/show/NCT01216995